Note Year ended Dec 2025 $’000 Year ended Dec 2024 $’000 Revenue from contracts with customers Licenses of intellectual property - royalty income 6 64,634 56,223 Licenses of intellectual property - milestone payments 6 – 80,502 Licenses of intellectual property - Rare Disease priority review voucher 6 – 76,518 64,634 213,243 Finance income 12,159 11,014 Gain on financial derivatives measured at fair value through profit and loss – 3,587 Other income 15 2 Net foreign currency gains 8,028 – Total income 84,836 227,846 Expenses Research and development costs (36,392) (32,970) Corporate and administrative costs (6,218) (4,701) Loss on financial derivatives measured at fair value through profit and loss (3,297) – Net foreign currency loss – (7,235) Total expenses (45,907) (44,906) Profit before income tax expense 38,929 182,940 Income tax expense 8 (8,493) (40,897) Profit after income tax expense for the year attributable to the owners of Neuren Pharmaceuticals Limited 30,436 142,043 Other comprehensive income Items that may be reclassified subsequently to profit or loss Foreign currency translation (26,339) 24,198 Other comprehensive income for the year, net of tax (26,339) 24,198 Total comprehensive income for the year attributable to the owners of Neuren Pharmaceuticals Limited 4,097 166,241 Cents Cents Basic earnings per share 9 23.73 111.17 Diluted earnings per share 9 23.27 108.61 CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 31 DECEMBER 2025 The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes Neuren Pharmaceuticals Limited Annual Report 2025 32
RkJQdWJsaXNoZXIy MjE2NDg3